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Abstract
Autonomic dysreflexia (AD) is a life-threatening complication of spinal cord injury (SCI) at T6
or above that results in an uncontrolled sympathetic discharge in response to noxious stimuli. It
is a symptom complex characterized by a lethal rise in blood pressure with dangerous conse-
quences. Autonomic dysreflexia is often secondary to urological, gastrointestinal, or gynecological
problems or manipulations. Early recognition and prompt treatment of AD is vital to prevent
complications, including death. Its management starts primarily with its prevention. Easy meas-
ures can avoid this high risk event, and physicians should be aware of the simple procedures and
the possible treatment cascade that could be undertaken. The purpose of this systematic review is
to review the clinical data on the mechanisms and pathophysiology of this condition and the
clinical evidence about the various strategies currently used to prevent and manage AD in the
SCI population; and to improve awareness of AD among cardiologists, family physicians and
medical personnel in the emergency department. (Cardiol J 2012; 19, 2: 215–219)
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Introduction
Autonomic dysreflexia (AD) is a potentially life-
threatening condition characterized by a sudden
uncontrolled sympathetic response secondary to
noxious stimuli resulting in a sudden rise in blood
pressure with dangerous consequences. It especial-
ly occurs in patients with an injury at level T6 or
above [1–4]. The higher the level of spinal cord in-
jury (SCI), the more severe the bouts of AD, as
measured by the level of hypertension. Another
important factor relating to the severity of AD is
the completeness of the spinal injury: only 27% of
patients with incomplete tetraplegia present with
signs of AD, compared to 91% of patients with tet-
raplegia with complete lesions [5]. In addition, the
AD reaction is provoked by a noxious stimulus en-
tering the spinal cord below the level of injury. If
more than one peripheral stimuli is present simul-
taneously, it seems that the reaction is more severe
and more readily activated [6].
The incidence of AD is reported as between
48% and 98% in patients with quadriplegia and high
paraplegia. It usually occurs within the first six
months after injury, but can occur up to 13 years
later [7].
Pathophysiology
It is known from animal experiments that au-
tonomic instability after SCI results from changes
occurring within the spinal and peripheral autonomic
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circuits, both in the acute and chronic stages after
injury. A noxious stimulus (i.e. one that might be
expected to cause pain or discomfort in a person
without SCI) below the level of the lesion produc-
es an afferent impulse that generates a generalized
sympathetic response, which in turn results in wide-
spread vasoconstriction, most significantly in the
splanchnic vasculature, which causes an increase
in peripheral resistance and a shunting of the nor-
mal blood that is congested, thereby forcing it to
enter into the general circulation [8, 9].
The combination of the increased vasoconstric-
tion and the increased fluid load in the vascular
space causes a potentially catastrophic increase
in blood pressure (BP). Systolic BP can increase to
as high as 300 mm Hg, diastolic BP to as high as
200 mm Hg [10–17].
The brain detects this hypertension crisis
through intact baroreceptors and stimulates the
parasympathetic nervous system in an attempt to
lower BP. The parasympathetic overactivity (and
lack of sympathetic tone) above the level of the le-
sion results in peripheral vasodilation and is thought
to be responsible for the headache, flushing and
sweating in the head and neck region, and the na-
sal congestion [9, 18].
Clinical features
Autonomic dysreflexia can present with a va-
riety of symptoms and can vary in intensity from
asymptomatic, to mild discomfort, to a life-threat-
ening emergency. Normally, patients with SCI at
T6 or above have systolic BP of 90 to 110 mm Hg.
A sudden 20 to 40 mm Hg increase of systolic and
diastolic BP over baseline that is frequently asso-
ciated with bradycardia may indicate AD. In addi-
tion, an elevation of systolic BP of 15 to 20 mm Hg
in adolescents, or higher than 15 mm Hg above
baseline in children, is significant and may suggest
AD [19, 20]. It is accompanied by at least one of the
following signs (sweating, piloerection, facial flush-
ing, cold peripheries), or symptoms (headache,
blurred vision, stuffy nose, chest tightness) [21–24].
The differential diagnosis includes migraine and
cluster headaches, essential hypertension, poste-
rior fossa tumors, pheochromocytoma and toxemia
of pregnancy [25].
Besides bradycardia, other cardiac abnormali-
ties may be encountered, such as cardiac arrhyth-
mias (atrial fibrillation, premature ventricular con-
traction, and atrioventricular conduction anomalies)
[26–28]. Like chronic hypertension, AD can lead to
cardiovascular damage. Cervical or high-thoracic
(T6 or above) severe SCI deprives patients of su-
praspinal sympathetic control of cardiovascular
functions that include coronary blood flow, cardiac
contractility, and heart rate. Disordered cardiac
control may account for the prevalence of asymp-
tomatic coronary artery disease after SCI. And ab-
normal peripheral vasomotor responses due to de-
centralized regulation of vascular tone and BP con-
trol are seen in these patients, who develop low
resting BP, orthostatic hypotension, and loss of
diurnal fluctuation of BP [29].
Precipitants
A variety of non-noxious or noxious stimuli can
trigger episodes of AD. The commonest triggering
factor is bladder distension because of urinary re-
tention or catheter blockage, and accounts for up
to 85% of cases. Pain or irritation within the co-
lorectal area is the second commonest cause, ac-
counting for 13% to 19% of cases. Constipation,
hemorrhoids, and anal fissures are frequently ob-
served in patients with SCI and contribute to epi-
sodes of AD [30]. In addition to urinary and gas-
trointestinal triggers, a long list of other potential
precipitative factors has been reported. Among the
more common of these are cutaneous triggers such
as pressure sores and ingrown toenails. In addition,
other factors include: urological endoscopic proce-
dures such as cystoscopy or urodynamics, urinary
infections, bladder calculi, surgical stimulation,
pregnancy or childbirth, and any other traumatic or
painful stimulus. Less common triggers include
deep vein thrombosis, pulmonary embolism, syrin-
gomyelia and sexual activity [30, 31].
Treatment
Early recognition of signs and symptoms of AD
is a major key to immediate and appropriate treat-
ment of this urgent condition. Late recognition or
inappropriate management may result in severe
hypertension and complications such as seizures,
intracranial and retinal hemorrhages, myocardial
irregularities, coma, and even death [32–37].
Treatment consists of identifying and remov-
ing the trigger for AD and managing symptoms to
prevent complications. The initial management of
an episode of AD involves placing the patient in an
upright position to take advantage of any orthostatic
reduction in BP. The next step in managing acute
AD must be to loosen any tight clothing and/or con-
strictive devices. This procedure allows further
blood pooling in vessel beds below the level of in-
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jury and removes possible triggers for peripheral
sensory stimulation [4, 38–40]. Blood pressures
have the potential of fluctuating quickly during an
AD episode. Therefore, pressures need to be moni-
tored every few minutes (every 2 to 5 min is com-
monly cited), until the individual is stabilized [18,
24]. Identifying the possible trigger and decreasing
afferent stimulation to the spinal cord appear to
comprise the most effective non-pharmaceutical
therapeutic strategy in clinical practice. Thus, it is
necessary to search for and eliminate the precipi-
tating stimulus, which, in 85% of cases, is related
either to bladder distention or to bowel impaction
[18, 30, 31]. When the inciting event is not appar-
ent, more severe precipitants of dysreflexia (e.g.
pulmonary embolism) must be considered and ruled
out [18, 41].
If signs and symptoms of AD persist despite
these measures, initiation of antihypertensive thera-
py is indicated. There are no studies to show the
threshold value at which the elevated BP becomes
dangerous [42]. As recommended in the Guidelines
of the Consortium for Spinal Cord Medicine for the
management of AD, non-pharmacologic measures
must be employed initially; if they fail, and systolic
BP continues to be at or above 150 mm Hg in an
adult, 140 mm Hg in an adolescent, 130 mm Hg in
a child six to 12 years old, or 120 mm Hg in a child
under five years old, some type of pharmacologic
agent should be initiated [24].
Antihypertensive medication should preferably
have a rapid onset and short duration of action [18].
Numerous pharmacologic agents (e.g. nifedipine,
nitrates, captopril, terazosin, prazosin, phenoxyben-
zamine, prostaglandin E2, sildenafil) have been pro-
posed for the management of AD episodes [18, 24].
Nifedipine and nitrates are the most common-
ly used agents. Traditionally recommended for AD
is immediate-release nifedipine through the bite and
swallow method. However, because of several re-
ports of serious adverse reactions occurring after
immediate-release nifedipine for hypertensive cri-
ses in other populations, the Joint National Com-
mittee on the Detection, Evaluation, and Treatment
of High Blood Pressure has discouraged use of this
drug [43].
Nitrates have been used for acute episodes of
AD. Before nitrates (e.g. nitroglycerin, isosorbide
dinitrate, or sodium nitroprusside) are adminis-
tered, a person with a SCI presenting with acute
AD should be questioned regarding use of sildena-
fil. If this agent has been used within the last 24 h,
it is recommended that an alternative, short-acting,
rapid-onset, non-nitrate antihypertensive agent be
used [11, 24]. Captopril is a specific competitive
inhibitor of angiotensin converting enzyme. A pro-
spective, open-label study and numerous expert
opinions suggest the use of captopril as a primary
medication in the management of AD. During an
acute episode of AD, 25 mg captopril is often ad-
ministered sublingually [24, 44–46]. Terazosin
and prazosin are long-acting, alpha-1 adrenoceptor
selective blocking agents. Selective alpha-1 block-
ade has been suggested as an appropriate pharma-
cologic choice in the management of AD because
of its added effect at the bladder level, which in-
cludes inhibition of the urinary sphincter and relax-
ation of the smooth muscles of blood vessels [47–
–50]. But, as a alpha-receptor blocker, tamsulosin
is not recommended in the acute treatment of AD.
Although sildenafil decreased resting BP, there was
no effect on the magnitude of AD resulting from
vibrostimulation in men with SCI [51]. In addition,
there have been reports on the use of beta-block-
ers, mecamylamine and, rarely, intravenous hy-
dralazine, sodium nitroprusside or diazoxide for the
general management of AD symptoms in subjects
with SCI [6, 51].
The resolution of the episode of AD should be
followed by monitoring of symptoms, BP, and heart
rate for at least 2 h to make sure it does not recur
[18, 24]. If the BP is well controlled and serious
causes are ruled out, the patient can be discharged
and other investigations can be done on an outpa-
tient basis [18].
Prevention
The key to successful management is preven-
tion through patient and family education, proper
bladder, bowel, and skin care, and identification and
avoidance of noxious stimuli. Unfortunately, the
level of awareness of AD among family physicians
and medical personnel in the emergency depart-
ment or ambulance services appears to be low, es-
pecially as it pertains to patients with SCI [24].
Clinicians, family members, and caregivers should
be aware that increased afferent stimulation (e.g.
via surgery, invasive investigational procedures,
and labor) in persons with SCI will increase their
risk for AD and that a variety of procedures can be
used to prevent AD episodes [18].
In patients with recurrent attacks, an alpha-
-adrenoceptor blocker may result in some suppres-
sion of dysreflexic symptoms; a nightly dose of ter-
azosin, 5 mg, or tamsulosin, 0.8 mg, may reduce the
frequency and severity of AD. Acute AD may be
precipitated by surgical, cystoscopic, urodynamic,
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and radiologic procedures. Prophylactic nifedipine,
10 mg, or nitropaste 2% could therefore be given
shortly before the procedure, especially if the pa-
tient is known to have recurrent acute AD episodes.
Prophylactic treatment of chronic patients with an
alpha-adrenoceptor blocker or premedication before
a procedure does not eliminate the need for careful
monitoring during provocative procedures [21, 35,
52, 53]. However, conservative management is not
always successful, and alternative strategies (e.g.
botulinum toxin, capsaicin, anticholinergics, sacral
denervation, bladder and urethral sphincter sur-
gery) are required to decrease afferent stimulation
from the urinary bladder, thereby preventing the
development of AD [20, 37].
Conclusions
As a result, AD can be quickly treated and re-
versed by consumers themselves, family members,
or pre-hospital providers. In most cases, the prompt
emptying of a patient’s bladder and/or bowels will
resolve most AD episodes, When other precipitants
may not be addressed in the pre-hospital setting,
the patient with acute AD and elevated BP should
be referred to the nearest emergency department
for management.
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